Jul 27, 2017 12:47 PM EDT
AMD Radeon RX Vega is all set to launch in the coming week but rumors about the upcoming gaming graphics card allege that it will have a limited supply issue. Similar to the launch of AMD's Fury series of GPU, there are rumors circulating that the stock of AMD Vega series will also be very limited at launch.
According to the inside source, the hardware circles; AMD looks to be once again having trouble with keeping up with the stock for their latest product. Reports claim that when the Radeon RX Vega series launches next week, not only will it be only available at some exclusive retailers but the stocks will also be severely limited, as reported by Segment Next.
However, this is surprising considering the fact that AMD Radeon RX Vega was meant to be company's counter to Nvidia's GTX 1070 and GTX 1080. The exact reason for this limited RX Vega stock is unclear as of now, however, several reports mention the introduction of the new HBM2 memory as a big factor in this.
Another possibility is that AMD is deliberately trying to down play GPU accessibility to not only increase the demand but also make sure that the cryptocurrency miners. According to the TweakTown, AMD will only make 16,000 units of Radeon RX Vega for consumers in the first few months of release.
The AMD Vega series will be officially unveiled at SIGGRAPH at the end of this month. Right now, there is no price tag known for these high-end GPUs but considering the fact that they are close to the performance of NVIDIA GTX 1080, a price tag of at least $400-450 is expected. The final price and performance also might decide whether people rush in to purchase the Radeon RX Vega GPU series or not. These all things will become clearer at SIGGRAPH.
2. Aug 21, 2018
Study: Length of opioid prescription spell highest risk for misuse after surgery
3. Aug 06, 2018
NASA Introduces First Batch Of Commercial Astronaut Crew
4. Jul 31, 2018
Pair of colliding stars spill radioactive molecules into space
2. Jul 26, 2018
New system can identify drugs to target 'undruggable' enzymes critical in many diseases
3. Jul 26, 2018
Health benefits of moderate drinking may be overstated, study finds